

EMA/382520/2021

European Medicines Agency decision P/0325/2021

of 12 August 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucravacitinib (EMA-002350-PIP03-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0325/2021

of 12 August 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucravacitinib (EMA-002350-PIP03-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bristol-Myers Squibb International Corporation on 13 July 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 June 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for deucravacitinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for deucravacitinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for deucravacitinib, film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Bristol-Myers Squibb International Corporation, Parc de l'Alliance, Avenue de Finlande 4, 1420 - Braine-l'Alleud, Belgium.

EMA/PDCO/191188/2021
Amsterdam, 25 June 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002350-PIP03-20

Scope of the application

Active substance(s):

Deucravacitinib

Condition(s):

Treatment of systemic lupus erythematosus

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb International Corporation

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb International Corporation submitted for agreement to the European Medicines Agency on 13 July 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 18 August 2020.

Supplementary information was provided by the applicant on 18 March 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee members agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of systemic lupus erythematosus

The waiver applies to:

- the paediatric population from birth to less than 5 years of age;
- film-coated tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of systemic lupus erythematosus

2.1.1. Indication(s) targeted by the PIP

Treatment of systemic lupus erythematosus despite receiving standard of care

Treatment of lupus nephritis despite receiving standard of care

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1: (This is the same study as Study 1 in EMEA-002350-PIP01-18.) Development of age appropriate formulation for paediatric use
Non-clinical studies	1	Study 2: (This is the same study as Study 2 in EMEA-002350-PIP01-18.) Definitive juvenile toxicity study in rats (DN18003)

Clinical studies	2	<p>Study 3:</p> <p>Double-blind, placebo-controlled, randomised withdrawal trial to evaluate safety and efficacy of deucravacitinib as add-on to standard of care in children from 5 years to less than 18 years of age with systemic lupus erythematosus</p> <p>Study 4:</p> <p>Open-label trial to evaluate pharmacokinetics, safety and efficacy of deucravacitinib as add-on to standard of care in children from 5 years to less than 18 years of age with lupus nephritis</p>
Extrapolation, modelling and simulation studies	2	<p>Study 5:</p> <p>Modelling and simulation study incorporating paediatric systemic lupus erythematosus data to evaluate the use of deucravacitinib in children from 5 years to less than 18 years of age with systemic lupus erythematosus.</p> <p>Study 6</p> <p>Modelling and simulation study incorporating paediatric lupus nephritis data to evaluate the use of deucravacitinib in children from 5 years to less than 18 years of age with systemic lupus erythematosus</p>
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2036
Deferral for one or more measures contained in the paediatric investigation plan:	Yes